All In Biotech

Drug Trial Radar · NCT03332095

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

Last checked: Nov 19, 2026Latest source record: Feb 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Jul 2, 2018

Primary completion

Aug 19, 2020

Study completion May 25, 2022

Sponsor

Sponsor type
NIH
First posted
Nov 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the pharmacokinetics, safety, and tolerability of doravirine (also called MK-1439 or DOR) and doravirine/lamivudine/tenofovir disoproxil fumarate (also called MK-1439A or DOR/3TC/TDF) in HIV-1-infected children and adolescents.

Conditions

  • HIV Infections

Interventions

  • Doravirine (DOR)Drug

    100 mg of DOR administered orally

  • Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)Drug

    DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg) once daily

  • Antiretroviral (ARV) medicationsDrug

    Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK) Parameter: Single-dose Area-under-the-curve (AUC0-∞) of Doravirine (DOR) (Cohort 1)Time frame: Measured during the entry (day 0) visit. Blood samples were drawn at pre-dose, and at 1, 2, 4, 8, 12, 24, 48 and 72 hours post-dose.
  2. PK Parameter: Single-dose Maximum Concentration (Cmax) of DOR (Cohort 1)Time frame: Measured during the entry (day 0) visit. Blood samples were drawn at pre-dose, and at 1, 2, 4, 8, 12, 24, 48 and 72 hours post-dose.
  3. PK Parameter: Single-dose 24 Hour-concentration (C24hr) of DOR (Cohort 1)Time frame: Measured during the entry (day 0) visit. Blood samples were drawn at pre-dose, and at 1, 2, 4, 8, 12, 24, 48 and 72 hours post-dose.
  4. Percentage of Participants With Grade 3 or Higher Adverse Events (AEs) Assessed as Related to Study DrugTime frame: Cohort 1: Measured from Day 0 through Week 2; Cohort 2: Measured from Day 0 through Week 24.
  5. Percentage of Participants With Serious Adverse Events (SAEs) Assessed as Related to Study DrugTime frame: Cohort 1: Measured from Day 0 through Week 2; Cohort 2: Measured from Day 0 through Week 24.
  6. Percentage of Participants With Permanent Discontinuation of Study Drug Due to Adverse Events Assessed as Related to Study DrugTime frame: Cohort 1: Measured from Day 0 through Week 2; Cohort 2: Measured from Day 0 through Week 24.
  7. Percentage of Participants With Grade 5 Adverse Events (Death) Regardless of Relationship to Study DrugTime frame: Cohort 1: Measured from Day 0 through Week 2; Cohort 2: Measured from Day 0 through Week 24.

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Univ. of Colorado Denver NICHD CRS

    Aurora, Colorado

  • Boston Medical Center Ped. HIV Program NICHD CRS

    Boston, Massachusetts

  • St. Jude Children's Research Hospital CRS

    Memphis, Tennessee

  • Seattle Children's Research Institute CRS

    Seattle, Washington

  • Soweto IMPAACT CRS

    Johannesburg, Gauteng, South Africa

  • Chiangrai Prachanukroh Hospital NICHD CRS

    Chiang Mai, Thailand

  • Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS

    Chiang Mai, Thailand

  • Siriraj Hospital ,Mahidol University NICHD CRS

    Bangkok, Bangkoknoi, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.